Big enough to deliver. Small enough to care.
Oncology deserves a research partner that understands its complexity — and treats every project like it matters. That means managing every engagement proactively, sharing recommendations early and often, and keeping projects on budget and on timeline. Here's what that looks like in practice.
Built differently for oncology.
Oncology, Exclusively
Most research partners this size cover oncology as one vertical among many. We don't. Every study, every panel relationship, and every methodology decision is built around oncology's specific dynamics — cancer-type nuance, rapidly shifting standards of care, and small, overlapping KOL communities. That's a specialization a generalist firm can't replicate by adding an oncology page to their website.
Led by Lived Experience, Not Just Tenure
Terri Crudup brings experience on the research side of oncology — and has lived it from the other side, as a two-time cancer survivor and patient advocate. As patient-centricity moves from a checkbox to a regulatory expectation, that's not a biographical detail. It's a working credential: every message and material we test is filtered through someone who has actually sat in the chair.
Backed by a Team Built for Oncology's Breadth
Terri leads the practice, but she's not the practice. She's backed by a team with deep experience across the oncology landscape, ready to bring the right expertise to every project.
An In-House Physician Panel — Not a Rented One
A panel we build and maintain ourselves means faster fielding and purpose-built recruitment for hard-to-reach oncology subspecialties, rather than waiting on a third-party panel vendor's availability.
Reach Across the Full Decision-Making Chain
C-suite executives, system and market access decision-makers, physicians and HCPs, pharmacists, and patients — one partner covering stakeholders that typically require three different vendors to reach.
Global Consistency Where You Need It
Offices across the US, EU, and APAC — built for the multi-market studies that matter to a global launch, not a US-only view with an international logo.
Speed That Doesn't Cost You Rigor
On a recent oncology engagement, AI-assisted synthesis brought fielding-to-insight time from 8 weeks to 6 — without changing the underlying methodology.
Investment That Goes Further, Without the Trade-Offs
On that same engagement, chart audit costs came down from $200K to $89K. We lead with rigor first — the efficiency is a byproduct of how we work, not a discount.
Compliant by Design, Not by Exception
We're EphMRA and BHBIA affiliated, GDPR compliant, and ISO 9001 certified. Informed consent and HCP compliance are built into how we field every study — so your legal and procurement teams don't slow down what your brand team needs fast.